Ranbaxy gets Australian OK for risperidone
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has received approval from Australia's Therapeutic Goods Administration for the registration of Ozidal risperidone 0.5mg, 1mg, 2mg, 3mg and 4mg tablets. The product is bioequivalent to and has the same therapeutic effect as Janssen-Cilag's reference product, Risperdal tablets.